%0 Journal Article
%T Prognostic relevance of high expression of kynurenine pathway markers in glioblastoma.
%A Jacquerie A
%A Hoeben A
%A Eekers DBP
%A Postma AA
%A Vanmechelen M
%A de Smet F
%A Ackermans L
%A Anten M
%A Severens K
%A Zur Hausen A
%A Broen MPG
%A Beckervordersandforth J
%J Sci Rep
%V 14
%N 1
%D 2024 06 28
%M 38951170
%F 4.996
%R 10.1038/s41598-024-65907-3
%X Glioblastoma (GBM) continues to exhibit a discouraging survival rate despite extensive research into new treatments. One factor contributing to its poor prognosis is the tumor's immunosuppressive microenvironment, in which the kynurenine pathway (KP) plays a significant role. This study aimed to explore how KP impacts the survival of newly diagnosed GBM patients. We examined tissue samples from 108 GBM patients to assess the expression levels of key KP markers-tryptophan 2,3-dioxygenase (TDO2), indoleamine 2,3-dioxygenase (IDO1/2), and the aryl hydrocarbon receptor (AhR). Using immunohistochemistry and QuPath software, three tumor cores were analyzed per patient to evaluate KP marker expression. Kaplan-Meier survival analysis and stepwise multivariate Cox regression were used to determine the effect of these markers on patient survival. Results showed that patients with high expression of TDO2, IDO1/2, and AhR had significantly shorter survival times. This finding held true even when controlling for other known prognostic variables, with a hazard ratio of 3.393 for IDO1, 2.775 for IDO2, 1.891 for TDO2, and 1.902 for AhR. We suggest that KP markers could serve as useful tools for patient stratification, potentially guiding future immunomodulating trials and personalized treatment approaches for GBM patients.